{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T14:04:28Z","timestamp":1792591468737,"version":"4.5.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Pediatr"],"DOI":"10.1007\/s00431-026-07122-y","type":"journal-article","created":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T08:34:49Z","timestamp":1780043689000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Cenobamate in pediatric drug-resistant epilepsy: real-world evidence from a two-center retrospective study"],"prefix":"10.1007","volume":"185","author":[{"given":"Sofia","family":"Taximi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Angeli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioanna","family":"Chranioti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitra","family":"Dimopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgios","family":"Vartzelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Argirios","family":"Dinopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,29]]},"reference":[{"issue":"7","key":"7122_CR1","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1542\/pir.2019-0134","volume":"41","author":"A Fine","year":"2020","unstructured":"Fine A, Wirrell EC (2020) Seizures in children. Pediatr Rev 41(7):321\u2013347. https:\/\/doi.org\/10.1542\/pir.2019-0134","journal-title":"Pediatr Rev"},{"issue":"6","key":"7122_CR2","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1111\/j.1528-1167.2009.02397.x","volume":"51","author":"P Kwan","year":"2010","unstructured":"Kwan P et al (2010) Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia 51(6):1069\u20131077. https:\/\/doi.org\/10.1111\/j.1528-1167.2009.02397.x","journal-title":"Epilepsia"},{"issue":"17","key":"7122_CR3","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1212\/WNL.0000000000011839","volume":"96","author":"B Sultana","year":"2021","unstructured":"Sultana B et al (2021) Incidence and prevalence of drug-resistant epilepsy: a systematic review and meta-analysis. Neurology 96(17):805\u2013817. https:\/\/doi.org\/10.1212\/WNL.0000000000011839","journal-title":"Neurology"},{"key":"7122_CR4","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.yebeh.2014.05.031","volume":"37","author":"KD Laxer","year":"2014","unstructured":"Laxer KD et al (2014) The consequences of refractory epilepsy and its treatment. Epilepsy Behav 37:59\u201370. https:\/\/doi.org\/10.1016\/j.yebeh.2014.05.031","journal-title":"Epilepsy Behav"},{"issue":"9","key":"7122_CR5","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.2589","volume":"12","author":"P Ioannou","year":"2022","unstructured":"Ioannou P et al (2022) The burden of epilepsy and unmet need in people with focal seizures. Brain Behav 12(9):e2589. https:\/\/doi.org\/10.1002\/brb3.2589","journal-title":"Brain Behav"},{"issue":"6","key":"7122_CR6","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1007\/s40263-021-00819-8","volume":"35","author":"R Roberti","year":"2021","unstructured":"Roberti R, De Caro C, Iannone LF, Zaccara G, Lattanzi S, Russo E (2021) Pharmacology of cenobamate: mechanism of action, pharmacokinetics, drug\u2013drug interactions and tolerability. CNS Drugs 35(6):609\u2013618. https:\/\/doi.org\/10.1007\/s40263-021-00819-8","journal-title":"CNS Drugs"},{"issue":"3","key":"7122_CR7","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s40263-025-01158-8","volume":"39","author":"A Strzelczyk","year":"2025","unstructured":"Strzelczyk A et al (2025) Post-marketing experience with cenobamate in the treatment of focal epilepsies: a multicentre cohort study. CNS Drugs 39(3):321\u2013331. https:\/\/doi.org\/10.1007\/s40263-025-01158-8","journal-title":"CNS Drugs"},{"key":"7122_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.seizure.2023.09.006","volume":"112","author":"KL Makridis","year":"2023","unstructured":"Makridis KL, Kaindl AM (2023) Real-world experience with cenobamate: a systematic review and meta-analysis. Seizure Eur J Epilepsy 112:1\u201310. https:\/\/doi.org\/10.1016\/j.seizure.2023.09.006","journal-title":"Seizure Eur J Epilepsy"},{"issue":"10","key":"7122_CR9","doi-asserted-by":"publisher","first-page":"6596","DOI":"10.1007\/s00415-024-12510-1","volume":"271","author":"S Lauxmann","year":"2024","unstructured":"Lauxmann S et al (2024) Cenobamate: real-world data from a retrospective multicenter study. J Neurol 271(10):6596\u20136604. https:\/\/doi.org\/10.1007\/s00415-024-12510-1","journal-title":"J Neurol"},{"key":"7122_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2024.107306","volume":"200","author":"S Aboumatar","year":"2024","unstructured":"Aboumatar S et al (2024) Reductions in concomitant antiseizure medication drug load during adjunctive cenobamate therapy: post-hoc analysis of a subset of patients from a phase 3, multicenter, open-label study. Epilepsy Res 200:107306. https:\/\/doi.org\/10.1016\/j.eplepsyres.2024.107306","journal-title":"Epilepsy Res"},{"issue":"12","key":"7122_CR11","doi-asserted-by":"publisher","first-page":"4712","DOI":"10.1111\/epi.18586","volume":"66","author":"V Soto\u2010Insuga","year":"2025","unstructured":"Soto\u2010Insuga V et al (2025) Real\u2010world use of cenobamate in pediatric focal epilepsies and developmental epileptic encephalopathies: a multicenter retrospective series. Epilepsia 66(12):4712\u20134724. https:\/\/doi.org\/10.1111\/epi.18586","journal-title":"Epilepsia"},{"issue":"10","key":"7122_CR12","doi-asserted-by":"publisher","first-page":"2909","DOI":"10.1111\/epi.18091","volume":"65","author":"R Roberti","year":"2024","unstructured":"Roberti R et al (2024) Adjunctive cenobamate in people with focal onset seizures: insights from the Italian Expanded Access Program. Epilepsia 65(10):2909\u20132922. https:\/\/doi.org\/10.1111\/epi.18091","journal-title":"Epilepsia"},{"key":"7122_CR13","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.seizure.2025.11.016","volume":"134","author":"D Samanta","year":"2026","unstructured":"Samanta D, Naik S (2026) Efficacy and safety of cenobamate in developmental and epileptic encephalopathies: a systematic review and meta-analysis. Seizure 134:86\u201396. https:\/\/doi.org\/10.1016\/j.seizure.2025.11.016","journal-title":"Seizure"},{"issue":"5","key":"7122_CR14","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1111\/epi.18308","volume":"66","author":"E Buhleier","year":"2025","unstructured":"Buhleier E et al (2025) A multicenter cohort study on the efficacy, retention, and tolerability of cenobamate in patients with developmental and epileptic encephalopathies. Epilepsia 66(5):1519\u20131528. https:\/\/doi.org\/10.1111\/epi.18308","journal-title":"Epilepsia"},{"issue":"4","key":"7122_CR15","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1111\/epi.18257","volume":"66","author":"CE Gjerulfsen","year":"2025","unstructured":"Gjerulfsen CE et al (2025) Cenobamate as add\u2010on treatment for SCN8A developmental and epileptic encephalopathy. Epilepsia 66(4):1119\u20131128. https:\/\/doi.org\/10.1111\/epi.18257","journal-title":"Epilepsia"},{"key":"7122_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2025.110787","volume":"173","author":"D Samanta","year":"2025","unstructured":"Samanta D (2025) Cenobamate in pediatric epilepsy and developmental and epileptic encephalopathies: efficacy, safety, and syndrome-specific considerations. Epilepsy Behav 173:110787. https:\/\/doi.org\/10.1016\/j.yebeh.2025.110787","journal-title":"Epilepsy Behav"},{"key":"7122_CR17","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.pediatrneurol.2024.09.023","volume":"161","author":"G Aungaroon","year":"2024","unstructured":"Aungaroon G, Cooke A, Ritter D, Krueger D, Horn P, Franz DN (2024) Cenobamate\u2019s efficacy for seizure treatment in Tuberous Sclerosis Complex. Pediatr Neurol 161:201\u2013207. https:\/\/doi.org\/10.1016\/j.pediatrneurol.2024.09.023","journal-title":"Pediatr Neurol"},{"key":"7122_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2022.108679","volume":"130","author":"RT Varughese","year":"2022","unstructured":"Varughese RT, Shah YD, Karkare S, Kothare SV (2022) Adjunctive use of cenobamate for pediatric refractory focal-onset epilepsy: a single-center retrospective study. Epilepsy Behav 130:108679. https:\/\/doi.org\/10.1016\/j.yebeh.2022.108679","journal-title":"Epilepsy Behav"},{"key":"7122_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.950171","volume":"13","author":"KL Makridis","year":"2022","unstructured":"Makridis KL et al (2022) Real-world experience treating pediatric epilepsy patients with cenobamate. Front Neurol 13:950171. https:\/\/doi.org\/10.3389\/fneur.2022.950171","journal-title":"Front Neurol"},{"issue":"6","key":"7122_CR20","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1111\/epi.18338","volume":"66","author":"S Beniczky","year":"2025","unstructured":"Beniczky S et al (2025) Updated classification of epileptic seizures: position paper of the International League Against Epilepsy. Epilepsia 66(6):1804\u20131823. https:\/\/doi.org\/10.1111\/epi.18338","journal-title":"Epilepsia"},{"key":"7122_CR21","doi-asserted-by":"publisher","unstructured":"Chung SS et al (2020) Randomized phase 2 study of adjunctive cenobamate in patients with uncontrolled focal seizures. Neurology 94(22). https:\/\/doi.org\/10.1212\/WNL.0000000000009530","DOI":"10.1212\/WNL.0000000000009530"},{"key":"7122_CR22","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.eplepsyres.2017.07.018","volume":"136","author":"G Ito","year":"2017","unstructured":"Ito G, Okumura A, Kanemoto K (2017) Efficacy of a third or later antiepileptic drug regimen according to epilepsy syndrome among adult patients. Epilepsy Res 136:103\u2013108. https:\/\/doi.org\/10.1016\/j.eplepsyres.2017.07.018","journal-title":"Epilepsy Res"},{"issue":"2","key":"7122_CR23","doi-asserted-by":"publisher","DOI":"10.1212\/CPJ.0000000000200133","volume":"13","author":"S Agashe","year":"2023","unstructured":"Agashe S et al (2023) Cenobamate in generalized epilepsy and combined generalized and focal epilepsy. Neurol Clin Pract 13(2):e200133. https:\/\/doi.org\/10.1212\/CPJ.0000000000200133","journal-title":"Neurol Clin Pract"},{"key":"7122_CR24","doi-asserted-by":"publisher","unstructured":"Cagigal R, Romero\u2010del\u2010Rincon C, Fernandez\u2010Perrone A, Cruz R, M\u00f8ller RS, Aledo\u2010Serrano A (2025) Lack of effectiveness and seizure worsening with cenobamate in pediatric patients with Dravet syndrome. Epilepsia 66(6). https:\/\/doi.org\/10.1111\/epi.18426","DOI":"10.1111\/epi.18426"},{"key":"7122_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2021.106592","volume":"172","author":"WE Rosenfeld","year":"2021","unstructured":"Rosenfeld WE, Nisman A, Ferrari L (2021) Efficacy of adjunctive cenobamate based on number of concomitant antiseizure medications, seizure frequency, and epilepsy duration at baseline: a post-hoc analysis of a randomized clinical study. Epilepsy Res 172:106592. https:\/\/doi.org\/10.1016\/j.eplepsyres.2021.106592","journal-title":"Epilepsy Res"},{"key":"7122_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.1042168","volume":"13","author":"H Hersi","year":"2022","unstructured":"Hersi H, Saarinen JT, Raitanen J, Peltola J (2022) Response to subsequent antiseizure medications after first antiseizure medication failure in newly diagnosed epilepsy. Front Neurol 13:1042168. https:\/\/doi.org\/10.3389\/fneur.2022.1042168","journal-title":"Front Neurol"},{"key":"7122_CR27","unstructured":"Neligan A, Sander JW (2015) The prognosis of epilepsy [Internet]. In: Epilepsy Society Clinical Guidelines. Epilepsy Society. [cited 2026 Februuary 11]. Available from: https:\/\/epilepsysociety.org.uk\/sites\/default\/files\/2020-08\/Chapter36Neligan2015.pdf"},{"key":"7122_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2024.110139","volume":"161","author":"S Auvin","year":"2024","unstructured":"Auvin S, Specchio N (2024) Pharmacotherapeutic strategies for drug-resistant epilepsy in children. Epilepsy Behav 161:110139. https:\/\/doi.org\/10.1016\/j.yebeh.2024.110139","journal-title":"Epilepsy Behav"},{"issue":"8","key":"7122_CR29","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1093\/brain\/awh200","volume":"127","author":"WFM Arts","year":"2004","unstructured":"Arts WFM (2004) Course and prognosis of childhood epilepsy: 5-year follow-up of the Dutch study of epilepsy in childhood. Brain 127(8):1774\u20131784. https:\/\/doi.org\/10.1093\/brain\/awh200","journal-title":"Brain"},{"key":"7122_CR30","doi-asserted-by":"publisher","unstructured":"Spencer DC, Roberts CM (2005) Stopping seizure medications in children: When is it safe? Neurology 64(12). https:\/\/doi.org\/10.1212\/WNL.64.12.E32","DOI":"10.1212\/WNL.64.12.E32"},{"key":"7122_CR31","unstructured":"Appleton RE, Cross JH (2015) Drug treatment of paediatric epilepsy [Internet]. In: Epilepsy Society Clinical Guidelines. Epilepsy Society. [cited 2026 February 11]. Available from: https:\/\/epilepsysociety.org.uk\/sites\/default\/files\/2020-08\/Chapter30AppletonCross2015.pdf"},{"issue":"12","key":"7122_CR32","doi-asserted-by":"publisher","first-page":"3016","DOI":"10.1111\/epi.17092","volume":"62","author":"WE Rosenfeld","year":"2021","unstructured":"Rosenfeld WE et al (2021) Post hoc analysis of a phase 3, multicenter, open\u2010label study of cenobamate for treatment of uncontrolled focal seizures: effects of dose adjustments of concomitant antiseizure medications. Epilepsia 62(12):3016\u20133028. https:\/\/doi.org\/10.1111\/epi.17092","journal-title":"Epilepsia"},{"key":"7122_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2023.107242","volume":"197","author":"DA Becker","year":"2023","unstructured":"Becker DA, Demko SA (2023) Dose reduction and discontinuation of concomitant antiseizure medications after initiating cenobamate: a retrospective review. Epilepsy Res 197:107242. https:\/\/doi.org\/10.1016\/j.eplepsyres.2023.107242","journal-title":"Epilepsy Res"},{"issue":"3","key":"7122_CR34","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1111\/ane.13659","volume":"146","author":"BJ Steinhoff","year":"2022","unstructured":"Steinhoff BJ et al (2022) Onset of efficacy and adverse events during cenobamate titration period. Acta Neurol Scand 146(3):265\u2013275. https:\/\/doi.org\/10.1111\/ane.13659","journal-title":"Acta Neurol Scand"},{"key":"7122_CR35","doi-asserted-by":"publisher","unstructured":"Klein P et al (2022) Long-term efficacy and safety from an open-label extension of adjunctive cenobamate in patients with uncontrolled focal seizures. Neurology 99(10). https:\/\/doi.org\/10.1212\/WNL.0000000000200792","DOI":"10.1212\/WNL.0000000000200792"},{"key":"7122_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebr.2025.100782","volume":"31","author":"A Plaquevent","year":"2025","unstructured":"Plaquevent A, Goff FL, Chastan N (2025) A French real-world experience with cenobamate in patients with drug-resistant focal epilepsy: a retrospective observational study. Epilepsy Behav Rep 31:100782. https:\/\/doi.org\/10.1016\/j.ebr.2025.100782","journal-title":"Epilepsy Behav Rep"},{"issue":"3","key":"7122_CR37","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1002\/epi4.12757","volume":"8","author":"V Villanueva","year":"2023","unstructured":"Villanueva V et al (2023) Real\u2010world safety and effectiveness of cenobamate in patients with focal onset seizures: outcomes from an expanded access program. Epilepsia Open 8(3):918\u2013929. https:\/\/doi.org\/10.1002\/epi4.12757","journal-title":"Epilepsia Open"},{"key":"7122_CR38","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.seizure.2023.07.026","volume":"111","author":"\u00c1 Beltr\u00e1n-Corbellini","year":"2023","unstructured":"Beltr\u00e1n-Corbellini \u00c1 et al (2023) Cenobamate in patients with highly refractory focal epilepsy: a retrospective real-world study. Seizure 111:71\u201377. https:\/\/doi.org\/10.1016\/j.seizure.2023.07.026","journal-title":"Seizure"},{"issue":"1","key":"7122_CR39","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1111\/epi.17134","volume":"63","author":"JW Sander","year":"2022","unstructured":"Sander JW, Rosenfeld WE, Halford JJ, Steinhoff BJ, Biton V, Toledo M (2022) Long\u2010term individual retention with Cenobamate in adults with focal seizures: Pooled data from the clinical development program. Epilepsia 63(1):139\u2013149. https:\/\/doi.org\/10.1111\/epi.17134","journal-title":"Epilepsia"},{"issue":"3","key":"7122_CR40","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1177\/08830738251357348","volume":"41","author":"BK Iwamoto","year":"2026","unstructured":"Iwamoto BK et al (2026) Adverse effects of Cenobamate in pediatric epilepsy: demographic considerations. J Child Neurol 41(3):336\u2013344. https:\/\/doi.org\/10.1177\/08830738251357348","journal-title":"J Child Neurol"}],"container-title":["European Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00431-026-07122-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00431-026-07122-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00431-026-07122-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T07:33:49Z","timestamp":1781768029000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00431-026-07122-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,29]]},"references-count":40,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["7122"],"URL":"https:\/\/doi.org\/10.1007\/s00431-026-07122-y","relation":{},"ISSN":["1432-1076"],"issn-type":[{"value":"1432-1076","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,29]]},"assertion":[{"value":"11 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"We confirm that we have read the Journal\u2019s position on issues involved in ethical publication and affirm that this report is consistent with those guidelines. The study protocol was approved by the Hospital\u2019s Ethics Committee (Protocol number 4956).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All patients\u2019 parents\/legal guardians verbally consented to provide relevant clinical information after receiving full disclosure about the study's purpose and data confidentiality protections.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"449"}}